Castle Biosciences, Inc. announced oral presentations on its DecisionDx? gene expression profile (GEP) tests for skin cancer at the American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting, held Nov. 19-21, 2021. DecisionDx-Melanoma is Castle?s risk-stratification GEP test that is designed to predict 5-year risk of metastasis, as well as metastasis to the sentinel lymph node (SLN), independent of traditional staging factors. The test?s Integrated Test Result (ITR) includes the traditional class designation of lowest risk (Class 1A), increased risk (Class 1B/2A) or highest risk (Class 2B), as well as a more precise risk prediction for both SLN positivity and risk of recurrence, distant metastasis and melanoma survival in patients with stage I, II or III melanoma through the i31- GEP algorithms (i31-SLNB and i31-Risk of Recurrence (ROR)). The i31-SLNB and i31-ROR are distinct, independently validated algorithms that integrate clinicopathologic features with the DecisionDx-Melanoma score.